Literature DB >> 8071862

Epibatidine, an alkaloid from the poison frog Epipedobates tricolor, is a powerful ganglionic depolarizing agent.

M Fisher1, D Huangfu, T Y Shen, P G Guyenet.   

Abstract

Epibatidine, a newly discovered alkaloid from the skin of Dendrobatidae frogs, has structural similarities to nicotine. We examined the effects of epibatidine on cardiorespiratory function and ganglionic synaptic transmission. Superior cervical or splanchnic sympathetic nerve discharge (sSND) and phrenic nerve discharge (PND) were recorded along with arterial pressure (AP) in urethane-anesthetized, paralyzed and artificially ventilated rats. Epibatidine administered i.v. at low doses (0.5-2 micrograms/kg) produced a transient increase in AP and sSND, followed by a decrease and return to baseline; this low dose of epibatidine also produced a dose-dependent increase in PND. At high doses (cumulative dose of 8-16 micrograms/kg), epibatidine produced bradycardia, a profound depression in sSND and a transient elimination of PND. After i.v. administration of the ganglionic blocker chlorisondamine (5 mg/kg), AP was still increased by 1 microgram/kg epibatidine (+39 +/- 11 mm Hg). This pressor effect was not altered by pretreatment with the alpha-1 adrenergic antagonist phentolamine (+40 +/- 10 mm Hg); however, it was blocked by additional pretreatment with the vasopressin antagonist [beta-mercapto-beta,beta-cyclopentamethylenepropiony1, O-ET-Tyr2,Val4,Arg8]vasopressin (50 micrograms/kg i.v.; +2 +/- 0.4 mm Hg). Low doses of epibatidine (0.5-2 micrograms/kg) produced firing of postganglionic neurons in a decentralized ganglion preparation and potentiated synaptic transmission; at high doses (cumulative dose of 8-16 micrograms/kg), the alkaloid blocked ganglionic synaptic transmission. These results suggest that epibatidine is a potent agonist of ganglionic nicotinic receptors and that the alkaloid elicits cardiorespiratory effects similar to those of nicotine.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071862

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  Quantitative Molecular Imaging of Neuronal Nicotinic Acetylcholine Receptors in the Human Brain with A-85380 Radiotracers.

Authors:  Shahrdad Lotfipour; Mark Mandelkern; Arthur L Brody
Journal:  Curr Med Imaging Rev       Date:  2011-05-01

2.  Absolute Configuration and Pharmacology of the Poison Frog Alkaloid Phantasmidine.

Authors:  Richard W Fitch; Barry B Snider; Quan Zhou; Bruce M Foxman; Anshul A Pandya; Jerrel L Yakel; Thao T Olson; Nour Al-Muhtasib; Yingxian Xiao; Kevin D Welch; Kip E Panter
Journal:  J Nat Prod       Date:  2018-04-19       Impact factor: 4.050

3.  Alpha3beta4-nicotinic receptors mediate adrenergic nerve- and peptidergic (CGRP) nerve-dependent vasodilation induced by nicotine in rat mesenteric arteries.

Authors:  S Eguchi; S Miyashita; Y Kitamura; H Kawasaki
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

4.  High affinity binding of epibatidine to serotonin type 3 receptors.

Authors:  Renaldo C Drisdel; Douglas Sharp; Tricia Henderson; Tim G Hales; William N Green
Journal:  J Biol Chem       Date:  2007-08-15       Impact factor: 5.157

Review 5.  Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography.

Authors:  Andrew G Horti; Yongjun Gao; Hiroto Kuwabara; Robert F Dannals
Journal:  Life Sci       Date:  2009-03-18       Impact factor: 5.037

6.  Nanoparticle-conjugated animal venom-toxins and their possible therapeutic potential.

Authors:  Archita Biswas; Aparna Gomes; Jayeeta Sengupta; Poulami Datta; Santiswarup Singha; Anjan Kr Dasgupta; Antony Gomes
Journal:  J Venom Res       Date:  2012-10-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.